Insights
Search Results
Case Studies
2.24.26
How Wilson Sonsini Helped Foresight Diagnostics with Its Growth, Scale-Up, and Acquisition
Foresight Diagnostics is a leading cancer diagnostics company founded in 2020 and spun out of Stanford University. Foresight has developed a novel liquid biopsy testing platform for the measurement of minimal residual disease that is significantly more sensitive than existing tests. Its technology, called PhasED-SeqTM, is based on a simple blood draw and next-generation sequencing. It is broadly applicable to a variety of cancers, and its ability to detect circulating tumor DNA at levels of 0.0001 percent (or one part-per-million) has the potential to provide actionable information to physicians and biopharmaceutical companies, thus enabling the development of a more proactive and personalized treatment approach.
Client Highlights
12.08.25
Wilson Sonsini Advises Foresight Diagnostics on Acquisition by Natera
On December 5, 2025, Natera, Inc., a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, announced that Natera has completed its acquisition of Foresight in an all-stock transaction consisting of a $275 million upfront payment with an additional $175 million in earnouts tied to the achievement of revenue- and reimbursement-based milestones. Wilson Sonsini Goodrich & Rosati advised Foresight on the transaction.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
Alerts
4.03.25
FDA’s LDT Final Rule Rejected by Federal District Court in Texas
As Wilson Sonsini previously reported,1 the U.S. Food and Drug Administration (FDA) had been preparing the industry to comply with the 2024 LDT Final Rule, which phases out the FDA’s enforcement discretion policy for laboratory developed tests (LDTs) and phases in device requirements starting in May 2025. But legal challenges against the LDT Final Rule have prevailed. On March 31, 2025, the U.S. District Court for the Eastern District of Texas vacated the LDT Final Rule, declaring that LDTs are not devices regulated by the FDA under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Rather, the court determined that LDTs are professional services regulated by the Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments of 1988 (CLIA).
Newsletters
6.10.24
The Life Sciences Report – June 2024
This latest edition features articles on biotech client Siolta Therapeutics, the use of safety and efficacy findings to extend drug exclusivity periods, life sciences venture financings for clients in 2023, and updated USPTO guidance for determining non-obviousness. The newsletter also includes details on the recent LaunchBio NextGen VC Forum in San Francisco, the firm’s Patents and Innovations Learning Library for in-house IP counsel, the latest episodes of the LaunchBio/Wilson Sonsini NextGen VC Podcast focused on life sciences investing, and the firm’s sponsorship of the National Inventors Hall of Fame Induction Ceremony, as well as select life sciences client highlights.
Newsletters
1.04.24
The Life Sciences Report – January 2024
This issue features articles on the firm’s Business Advisory Practice supporting Nervosave Therapeutics’ U.S. expansion; the USPTO’s forthcoming guidance on AI innovation protection; option pool sizes for life sciences companies; life sciences venture financings for clients in 2H 2022 and 1H 2023; and Congress’s attempts to improve medical diagnostics patent eligibility. It also includes a client interview with SonoThera CEO Kenneth Greenberg, an article on DOJ’s incentives for life sciences companies to self-disclose misconduct, and a Q&A with Ed Shenkan on decreasing risk from medical device concept to commercialization, as well as details on recent life sciences-focused NextGen VC Forums hosted by Wilson Sonsini and LaunchBio, the 28th annual Phoenix Conference and 2023 Life Sciences Investment Forum, and select life sciences client highlights.
Client Highlights
9.07.23
Wilson Sonsini Advises Idorsia on Reacquisition of Global Rights to Aprocitentan
On September 6, 2023, Idorsia Ltd announced that it has entered into an agreement with Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the return of worldwide rights for aprocitentan to Idorsia. Aprocitentan is an oral, dual endothelin receptor antagonist currently under review with health authorities for the treatment of patients with resistant hypertension. In return, Idorsia is committed to pay up to 306 million Swiss francs, or about $343 million, subject to marketing application approval by the U.S. FDA and Europe’s EMA. Wilson Sonsini Goodrich & Rosati represented Idorsia in the transaction.
Client Highlights
4.28.23
Wilson Sonsini Advises Foresight Diagnostics on $58.75 Million Series B
On April 27, 2023, Foresight Diagnostics, Inc, a leading developer of ultrasensitive cancer detection tests, announced the close of an oversubscribed Series B financing round of $58.75 million. The financing was led by Foresite Capital, with participation by Civilization Ventures, Bluebird Ventures, Pear Ventures, Agent Capital, Stanford University, and The University of Colorado Healthcare Innovation Fund. Wilson Sonsini Goodrich & Rosati advised Foresight on corporate, IP, licensing, and business advisory matters related to the transaction.
Press Releases
6.04.19
Matthew J. Meyer Joins Wilson Sonsini's Life Sciences Practice
- Meyer to lead development of firm's life science business advisory practice—brings extensive start-up and established biopharma, med tech and diagnostic commercial, business development and strategic experience to role -